Finance

Beta
Lists
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$292.58
+2.26%
(+6.46) 1D
$302.50
+3.39% (+9.92)
After hours
Closed: Jun 3, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALNY...
Open
$284.48
High
$293.16
Low
$283.10
Mkt. cap
39.06B
Avg. vol.
1.07M
Volume
0.00
P/E ratio
69.69
52-wk high
$495.55
52-wk low
$283.10
EPS
$4.20
Beta
0.29
Shares outstanding
133.51M
No. of employees
2K
Open
$284.48
High
$293.16
Low
$283.10
Mkt. cap
39.06B
Avg. vol.
1.07M
Volume
0.00
P/E ratio
69.69
52-wk high
$495.55
52-wk low
$283.10
EPS
$4.20
Beta
0.29
Shares outstanding
133.51M
No. of employees
2K
News stories
From sources across the web
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEOYvonne Greenstreet
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com
Last report
Apr 30, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$1.99 / $1.49
+33.72%beat
Revenue / Est. (USD)
1.17B / 1.11B
+4.71%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
773.69M
1.25B
1.10B
1.17B
Cost of goods sold
142.95M
200.15M
267.72M
211.12M
Cost of revenue
142.95M
200.15M
267.72M
211.12M
Research and development expenses
323.62M
358.81M
372.22M
364.87M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
323.31M
322.08M
325.37M
322.55M
Operating expense
646.94M
680.89M
697.59M
687.42M
Total operating expenses
789.89M
881.04M
965.32M
898.54M
Operating income
-16.20M
367.98M
131.72M
268.64M
Other non operating income
-5.05M
-74.15M
92.98M
-4.30M
EBT including unusual items
-35.36M
238.97M
161.14M
221.65M
EBT excluding unusual items
-34.01M
278.12M
121.99M
221.65M
Income tax expense
30.92M
-12.12M
-25.28M
15.66M
Effective tax rate
-87.45%
-5.07%
-15.69%
7.07%
Other operating expenses
-
-
-
-
Net income
-66.28M
251.08M
186.42M
205.99M
Net profit margin
-8.57%
20.10%
16.99%
17.65%
Earnings per share
0.32
2.90
1.25
1.99
Interest and investment income
27.49M
28.68M
26.63M
26.60M
Interest expense
-40.25M
-44.40M
-129.34M
-69.29M
Net interest expenses
-12.76M
-15.72M
-102.71M
-42.69M
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.26M
381.78M
145.22M
282.19M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer